Shionogi Shares Update on EXPERIENCE Trials for Fragile X скачать в хорошем качестве

Shionogi Shares Update on EXPERIENCE Trials for Fragile X

Juan Carlos Gomez, MD, MBA, Chief Medical Officer at Shionogi, provides an update on the status of the EXPERIENCE clinical trials of zatolmilast for Fragile X syndrome. Enrollment is now closed for the adult study (EXPERIENCE-301), and the adolescent study (EXPERIENCE-204) is in its final phase. These trials build on years of research, including early work funded by FRAXA Research Foundation. This video is republished with permission from Shionogi. Learn more about FRAXA’s role in advancing treatment options for Fragile X syndrome at fraxa.org. FRAXA’s mission is to find effective treatments and ultimately a cure for Fragile X syndrome. We directly fund research grants and fellowships at top universities around the world. We partner with biomedical and pharmaceutical companies, large and small, to bridge the gap between research discoveries and actual treatments. Treatments for Fragile X are likely to help people affected by autism, Alzheimer’s, and other brain disorders. To learn more about FRAXA's Fragile X syndrome research, to get involved with Fragile X awareness and events or to donate to FRAXA research, visit www.fraxa.org Let's Connect Facebook:   / fraxaresearch   Instagram:   / fraxaresearch   LinkedIn:   / fraxa-research-foundation   Reddit:   / fragilexreseach   Website: https://www.fraxa.org